Moderna stock is at a crossroads. Is the path forward beneficial or painful for mRNA?
Moderna (ARNM), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared a striking 838.4% between 2020 and 2022. But the company is now entering a new era to demonstrate that its mRNA technology can go beyond COVID-19. With new vaccine approvals, an expanding pipeline and ambitious bets on…